• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Castle Biosciences (CSTL) Stock Climbs On Higher Sales Outlook Despite Margin Pressure

    Simply Wall St·08/01/2026 01:22:28
    Listen to the news

    Castle Biosciences stock came into the print already on a strong run, with double digit gains over the past month, then jumped another 4.5% to about US$28 after the Q2 release. That kind of move suggests traders see more than just a routine quarter. The headline is simple: Revenue reached US$103.5m and management lifted full year sales guidance, while the income statement still showed a small loss. The market is clearly focusing on the stronger top line and higher outlook more than the loss, at least for now.

    Is Castle Biosciences stock a genuine mispricing story at a modelled fair value of about US$71.61 against a US$28 share price, or just an expensive 2.4x P/S premium? Compare that gap using the valuation analysis for Castle Biosciences

    Q2 2026 Earnings Summary

    • Revenue, Q2 2026 vs. Q2 2025: US$103.5m vs. US$86.2m (approximately 20% growth)
    • Net Income, Q2 2026 vs. Q2 2025: loss of US$2.1m vs. profit of US$4.5m (shifted from profit to loss)
    • Basic EPS, Q2 2026 vs. Q2 2025: loss of US$0.07 per share vs. profit of US$0.16 per share (shifted from profit to loss)
    • Adjusted EBITDA, Q2 2026 vs. Q2 2025: US$12.4m vs. US$10.4m (approximately 19% growth)

    Prefer clear visuals instead of another wall of earnings tables and footnotes? See Castle Biosciences' full valuation picture at a glance in the company report for Castle Biosciences.

    NasdaqGM:CSTL Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    NasdaqGM:CSTL Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Castle Biosciences bull case: growth engines hitting key markers

    The optimistic view on Castle Biosciences is that it is a precision diagnostics growth story backed by real adoption, better evidence and improving economics. Q2 lines up with that in several areas. Revenue grew 20% year on year, and when you strip out DecisionDx‑SCC and IDgenetix, growth was about 40%, which is where the long term story is supposed to come from. TissueCypher volumes increased 63% to 14,988 reports, and management is still talking about roughly 50% full year growth. DecisionDx‑Melanoma volumes ticked higher and were supported by a new prospective multicenter study that aligned with NCCN risk thresholds. AdvanceAD‑Tx is still early but passed an important reimbursement milestone with a unanimous crosswalk panel vote and a proposed US$3,675 CLFS rate, which directly supports the payer coverage part of the bull case.

    Bear case on margins and reimbursement gets fresh support

    The cautious view is that reimbursement risk and scaling costs keep Castle Biosciences on a funding treadmill and cap profitability. This quarter does not fully dispel that. GAAP gross margin moved from 77.3% to 74.9%, and adjusted gross margin shifted from 79.5% to 76.3%, while management now guides to low to mid 70s for the year. That aligns with concern about structurally lower margins as volumes grow. Operating expenses climbed to US$106.6m from US$90.4m, helped by higher personnel and lab costs, and GAAP swung from a US$4.5m profit to a US$2.1m loss even with higher adjusted EBITDA. DecisionDx‑SCC still lacks clear Medicare resolution, which keeps the reimbursement overhang alive even as other franchises progress.

    Compare Castle Biosciences' revenue momentum and margin pressure against what institutional investors are expecting. See the consensus price target analysis for Castle Biosciences

    Stay Ahead With Castle Biosciences Insights

    If the gap between Castle Biosciences' recent revenue growth and its modelled fair value has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the story develops. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the key updates that matter to your holdings. For a broader view on sentiment and potential catalysts, tap into crowd views and debate through the Community. This way you can spot potential turning points, surface hidden risks early and stay ahead of the market.

    Seeking Alternatives Beyond Castle Biosciences?

    Fresh ideas can move fast. Some stocks are already building breakout momentum while others stay under the radar for now. Do your homework before the crowd catches up and act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.